Cargando…

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

BACKGROUND: Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk. The study assesses the cost-effectiveness of palivizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentley, Anthony, Filipovic, Ivana, Gooch, Katherine, Büsch, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735492/
https://www.ncbi.nlm.nih.gov/pubmed/23919494
http://dx.doi.org/10.1186/2191-1991-3-18
_version_ 1782279654206341120
author Bentley, Anthony
Filipovic, Ivana
Gooch, Katherine
Büsch, Katharina
author_facet Bentley, Anthony
Filipovic, Ivana
Gooch, Katherine
Büsch, Katharina
author_sort Bentley, Anthony
collection PubMed
description BACKGROUND: Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of hospitalisation with RSV in the United Kingdom (UK). METHODS: A decision tree model was developed to reflect the clinical pathway of infants at high risk of severe RSV infection who receive either prophylaxis with palivizumab or no prophylaxis. The main outcome was the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed to assess the degree of uncertainty surrounding the results. A threshold analysis considered the impact of clinical and environmental risk factors on the cost-effectiveness in the subgroup of preterm infants 33–35 weeks gestational age (wGA). RESULTS: Prophylaxis with palivizumab compared with no prophylaxis is associated with the following ICERs; £33,216 for infants with congenital heart disease; £19,168 for infants with chronic lung disease; £3,845 for preterm infants < 29 wGA; £30,205 for preterm infants 29–32 wGA; and £99,056 for preterm infants 33–35 wGA. One-way sensitivity analysis suggests that these results are highly sensitive to the input data. Threshold analysis in the preterm 33–35 wGA subgroup demonstrates that an adjusted RSV-hospitalisation baseline risk of 17.94% or higher would result in an ICER below the £30,000 per quality-adjusted life-year threshold. DISCUSSION: Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources.
format Online
Article
Text
id pubmed-3735492
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-37354922013-08-07 A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom Bentley, Anthony Filipovic, Ivana Gooch, Katherine Büsch, Katharina Health Econ Rev Research BACKGROUND: Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of hospitalisation with RSV in the United Kingdom (UK). METHODS: A decision tree model was developed to reflect the clinical pathway of infants at high risk of severe RSV infection who receive either prophylaxis with palivizumab or no prophylaxis. The main outcome was the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed to assess the degree of uncertainty surrounding the results. A threshold analysis considered the impact of clinical and environmental risk factors on the cost-effectiveness in the subgroup of preterm infants 33–35 weeks gestational age (wGA). RESULTS: Prophylaxis with palivizumab compared with no prophylaxis is associated with the following ICERs; £33,216 for infants with congenital heart disease; £19,168 for infants with chronic lung disease; £3,845 for preterm infants < 29 wGA; £30,205 for preterm infants 29–32 wGA; and £99,056 for preterm infants 33–35 wGA. One-way sensitivity analysis suggests that these results are highly sensitive to the input data. Threshold analysis in the preterm 33–35 wGA subgroup demonstrates that an adjusted RSV-hospitalisation baseline risk of 17.94% or higher would result in an ICER below the £30,000 per quality-adjusted life-year threshold. DISCUSSION: Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources. Springer 2013-08-06 /pmc/articles/PMC3735492/ /pubmed/23919494 http://dx.doi.org/10.1186/2191-1991-3-18 Text en Copyright ©2013 Bentley et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bentley, Anthony
Filipovic, Ivana
Gooch, Katherine
Büsch, Katharina
A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
title A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
title_full A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
title_fullStr A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
title_full_unstemmed A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
title_short A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
title_sort cost-effectiveness analysis of respiratory syncytial virus (rsv) prophylaxis in infants in the united kingdom
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735492/
https://www.ncbi.nlm.nih.gov/pubmed/23919494
http://dx.doi.org/10.1186/2191-1991-3-18
work_keys_str_mv AT bentleyanthony acosteffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT filipovicivana acosteffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT goochkatherine acosteffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT buschkatharina acosteffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT bentleyanthony costeffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT filipovicivana costeffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT goochkatherine costeffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom
AT buschkatharina costeffectivenessanalysisofrespiratorysyncytialvirusrsvprophylaxisininfantsintheunitedkingdom